Syros Pharmaceuticals, Inc. (SYRS) Balance Sheet
SYRS balance sheet, 2023
December 31, 2023 · U.S. dollars$168.2M assets = $151.5M liabilities + $16.7M equity
Both columns are drawn to the same scale: what SYRS owns equals what it owes plus shareholders’ equity. Hover a block for its value.
SYRS financial health
Descriptive bands, not a rating. Fiscal 2023.
SYRS balance sheet trends, 2014–2023
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $61.5M2014 | $168.2M2023 | +11.8%/yr | |
| Total liabilities | $1.3M2014 | $151.5M2023 | +70.4%/yr | |
| Shareholders’ equity | $60.2M2014 | $16.7M2023 | −13.3%/yr | |
| Cash & short-term investments | $60.4M2014 | $139.5M2023 | +9.8%/yr | |
| Total debt | $339,0002014 | $62.1M2023 | +78.4%/yr | |
| Net cash (debt) | $60.1M2014 | $77.5M2023 | +$17.4M | |
| Working capital | $59.3M2014 | $108.3M2023 | +$49.0M | |
| Book value per share | $13.632021 | $0.592023 | −79.2%/yr | |
| Current ratio | 48.362014 | 3.952023 | −44.40 | |
| Debt / equity | 0.012014 | 3.732023 | +3.72 | |
| Shares outstanding | 6.3M2021 | 28.3M2023 | +112.8%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SYRS assets
SYRS liabilities and equity
SYRS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
SYRS balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $139.5M | $202.3M | $130.4M | $174.0M | $91.4M | $99.7M | $72.0M | $83.6M | $35.9M | $60.4M |
| Cash & equivalents | $139.5M | $167.5M | $92.3M | $174.0M | $41.4M | $49.9M | $32.2M | $58.6M | $35.9M | $60.4M |
| Short-term investments | $0 | $34.8M | $38.1M | $0 | $50.0M | $49.8M | $39.8M | $25.0M | $25.0M | $25.0M |
| Receivables | $0 | $1.7M | $3.0M | $2.3M | $20.2M | $0 | $0 | $867,000 | $0 | $867,000 |
| Inventory | $0 | $1 | $0 | $1 | $290,000 | $0 | $0 | $1 | $0 | $0 |
| Other current assets | $5.5M | $7.4M | $3.2M | $2.2M | $2.6M | $2.1M | $1.1M | $1.0M | $540,000 | $0 |
| Total current assets | $145.0M | $211.4M | $136.6M | $178.6M | $114.5M | $101.7M | $73.2M | $85.5M | $36.4M | $60.5M |
| Property, plant & equipment (net) | $19.5M | $24.7M | $27.3M | $29.6M | $31.9M | $3.9M | $3.9M | $4.8M | $4.8M | $881,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $13.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $3.7M | $8.4M | $6.0M | $5.1M | $3.6M | $1.2M | $1.4M | $965,000 | $2.4M | $70,000 |
| Total assets | $168.2M | $244.5M | $182.9M | $213.2M | $150.0M | $106.8M | $78.5M | $91.3M | $43.6M | $61.5M |
| Liabilities | ||||||||||
| Accounts payable | $11.5M | $6.4M | $3.7M | $3.6M | $5.9M | $3.3M | $2.3M | $2.4M | $5.0M | $928,000 |
| Short-term debt | $9.0M | $2.1M | $2.0M | $1.7M | $1.3M | $9,000 | $47,000 | $168,000 | $133,000 | $133,000 |
| Deferred revenue | — | $4.3M | $10.2M | $12.2M | $5.7M | $1.9M | $355,000 | $550,000 | — | — |
| Total current liabilities | $36.7M | $30.8M | $31.5M | $28.6M | $23.5M | $19.5M | $12.4M | $9.6M | $8.0M | $1.3M |
| Long-term debt | $34.6M | $40.6M | $40.3M | $39.6M | $621,000 | $22,000 | $6,000 | $53,000 | $206,000 | $206,000 |
| Lease obligations | $20.9M | $22.9M | $24.9M | $26.7M | $25.9M | $31,000 | $53,000 | $221,000 | — | — |
| Other long-term liabilities | $80.3M | $45.3M | $26.0M | $54.5M | $46.7M | $8.6M | $745,000 | $1.1M | $1.4M | $0 |
| Total liabilities | $151.5M | $116.8M | $97.7M | $122.7M | $70.8M | $28.2M | $13.2M | $10.7M | $9.6M | $1.3M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $26,000 | $20,000 | $61,000 | $56,000 | $43,000 | $34,000 | $26,000 | $23,000 | $2,000 | $1,000 |
| Retained earnings (deficit) | −$722.8M | −$558.2M | −$463.6M | −$377.0M | −$293.0M | −$217.5M | −$155.3M | −$101.3M | −$53.5M | −$23.7M |
| Treasury stock | — | — | — | — | — | — | $0 | $0 | — | — |
| Accumulated other comprehensive income | — | $102,000 | −$79,000 | $0 | $24,000 | −$3,000 | −$42,000 | −$9,000 | −$931,000 | −$428,000 |
| Minority interest | — | — | — | — | — | — | $0 | $0 | — | — |
| Total shareholders' equity | $16.7M | $127.7M | $85.2M | $90.6M | $79.2M | $78.6M | $65.3M | $80.6M | $34.0M | $60.2M |
| Key figures | ||||||||||
| Total debt | $62.1M | $63.6M | $65.2M | $66.2M | $25.9M | $31,000 | $53,000 | $221,000 | $339,000 | $339,000 |
| Net cash (debt) | $77.5M | $138.7M | $65.2M | $107.8M | $65.5M | $99.6M | $72.0M | $83.4M | $35.6M | $60.1M |
| Working capital | $108.3M | $180.6M | $105.1M | $149.9M | $91.0M | $82.2M | $60.7M | $75.9M | $28.5M | $59.3M |
| Tangible book value | $16.7M | $127.7M | $85.2M | $90.6M | $79.2M | $78.6M | $65.3M | $80.6M | $34.0M | $60.2M |
| Book value per share | $0.59 | $10.11 | $13.63 | — | — | — | — | — | — | — |
| Shares outstanding | 28.3M | 12.6M | 6.3M | — | — | — | — | — | — | — |
| Current ratio | 3.95 | 6.87 | 4.33 | 6.24 | 4.87 | 5.21 | 5.89 | 8.94 | 4.58 | 48.36 |
| Quick ratio | 3.80 | 6.63 | 4.23 | 6.16 | 4.74 | 5.10 | 5.80 | 8.83 | 4.51 | 48.93 |
| Debt / equity | 3.73 | 0.50 | 0.76 | 0.73 | 0.33 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Equity / assets | 9.9% | 52.2% | 46.6% | 42.5% | 52.8% | 73.6% | 83.2% | 88.3% | 78.0% | 98.0% |
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $58.3M | $79.0M | $108.3M | $139.5M | $112.2M | $144.0M | $165.8M | $202.3M | $244.5M | $86.3M | $110.3M | $130.4M |
| Cash & equivalents | $58.3M | $79.0M | $83.5M | $139.5M | $112.2M | $115.4M | $104.8M | $167.5M | $171.5M | $59.1M | $69.6M | $92.3M |
| Short-term investments | — | — | $24.8M | $0 | $0 | $28.5M | $61.0M | $34.8M | $72.9M | $27.2M | $40.7M | $38.1M |
| Receivables | $0 | $0 | $0 | $0 | $1.7M | $1.8M | $1.8M | $1.7M | $1.8M | $2.3M | $3.2M | $3.0M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1 | $1 | $1 | $0 | $0 |
| Other current assets | $5.7M | $6.0M | $3.9M | $5.5M | $8.6M | $6.9M | $6.1M | $7.4M | $6.1M | $3.4M | $3.0M | $3.2M |
| Total current assets | $63.9M | $84.9M | $112.2M | $145.0M | $122.5M | $152.6M | $173.6M | $211.4M | $252.3M | $91.9M | $116.5M | $136.6M |
| Property, plant & equipment (net) | $17.6M | $18.2M | $18.9M | $19.5M | $20.1M | $23.0M | $23.9M | $24.7M | $25.7M | $25.9M | $26.7M | $27.3M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.6M | $13.0M |
| Other non-current assets | $3.5M | $3.6M | $3.7M | $3.7M | $5.2M | $5.3M | $7.7M | $8.4M | $6.8M | $8.4M | $6.2M | $6.0M |
| Total assets | $85.0M | $106.7M | $134.7M | $168.2M | $147.8M | $181.0M | $205.3M | $244.5M | $284.7M | $126.2M | $152.1M | $182.9M |
| Liabilities | ||||||||||||
| Accounts payable | $9.6M | $7.5M | $11.3M | $11.5M | $2.9M | $6.7M | $2.8M | $6.4M | $13.0M | $6.1M | $2.8M | $3.7M |
| Short-term debt | $2.6M | $2.5M | $14.1M | $9.0M | $6.2M | $2.2M | $5.9M | $2.1M | $2.1M | $10.8M | $5.8M | $2.0M |
| Deferred revenue | — | — | — | — | $139,000 | $2.2M | $3.2M | $4.3M | $1.6M | $3.6M | $7.8M | $10.2M |
| Total current liabilities | $28.4M | $24.5M | $37.3M | $36.7M | $28.4M | $28.4M | $23.6M | $30.8M | $38.4M | $38.9M | $27.6M | $31.5M |
| Long-term debt | $41.1M | $40.9M | $29.7M | $34.6M | $39.4M | $40.9M | $39.1M | $40.6M | $40.5M | $34.0M | $38.8M | $40.3M |
| Lease obligations | $19.1M | $19.7M | $20.3M | $20.9M | $21.4M | $21.9M | $22.4M | $22.9M | $23.5M | $24.0M | $24.5M | $24.9M |
| Other long-term liabilities | $26.6M | $47.6M | $52.7M | $80.3M | $43.7M | $38.4M | $35.9M | $45.3M | $76.6M | $22.3M | $23.0M | $26.0M |
| Total liabilities | $96.1M | $113.1M | $119.7M | $151.5M | $111.5M | $107.7M | $98.6M | $116.8M | $155.6M | $95.2M | $89.3M | $97.7M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $27,000 | $26,000 | $26,000 | $26,000 | $21,000 | $20,000 | $20,000 | $20,000 | $20,000 | $62,000 | $61,000 | $61,000 |
| Retained earnings (deficit) | −$756.2M | −$749.8M | −$726.5M | −$722.8M | −$658.4M | −$618.3M | −$582.0M | −$558.2M | −$553.5M | −$523.2M | −$488.7M | −$463.6M |
| Accumulated other comprehensive income | — | $0 | $0 | — | — | $49,000 | $263,000 | $102,000 | −$226,000 | −$313,000 | −$273,000 | −$79,000 |
| Total shareholders' equity | −$11.1M | −$6.4M | $15.1M | $16.7M | $36.3M | $73.2M | $106.8M | $127.7M | $129.2M | $31.0M | $62.7M | $85.2M |
| Key figures | ||||||||||||
| Total debt | $60.2M | $60.7M | $61.7M | $62.1M | $64.7M | $62.8M | $65.3M | $63.6M | $64.0M | $66.7M | $67.0M | $65.2M |
| Net cash (debt) | −$2.0M | $18.3M | $46.6M | $77.5M | $47.5M | $81.2M | $100.5M | $138.7M | $180.5M | $19.6M | $43.3M | $65.2M |
| Working capital | $35.5M | $60.4M | $74.9M | $108.3M | $94.1M | $124.3M | $150.1M | $180.6M | $213.9M | $53.0M | $88.9M | $105.1M |
| Tangible book value | −$11.1M | −$6.4M | $15.1M | $16.7M | $36.3M | $73.2M | $106.8M | $127.7M | $129.2M | $31.0M | $62.7M | $85.2M |
| Book value per share | −$0.28 | −$0.16 | $0.39 | $0.56 | $1.30 | $2.62 | $3.83 | $4.60 | $13.72 | $4.86 | $9.95 | $13.54 |
| Shares outstanding | 39.3M | 39.3M | 39.0M | 29.5M | 28.0M | 27.9M | 27.8M | 27.8M | 9.4M | 6.4M | 6.3M | 6.3M |
| Current ratio | 2.25 | 3.46 | 3.01 | 3.95 | 4.31 | 5.38 | 7.37 | 6.87 | 6.57 | 2.36 | 4.22 | 4.33 |
| Quick ratio | 2.05 | 3.22 | 2.90 | 3.80 | 4.01 | 5.14 | 7.12 | 6.63 | 6.41 | 2.28 | 4.11 | 4.23 |
| Debt / equity | — | — | 4.10 | 3.73 | 1.78 | 0.86 | 0.61 | 0.50 | 0.50 | 2.15 | 1.07 | 0.76 |
| Equity / assets | −13.1% | −6.0% | 11.2% | 9.9% | 24.6% | 40.5% | 52.0% | 52.2% | 45.4% | 24.6% | 41.3% | 46.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 27, 2024); data from EODHD.
SYRS financial position
At the end of fiscal 2023 (December 31, 2023), Syros Pharmaceuticals had total assets of $168.2 million (down 31.2% from a year earlier), total liabilities of $151.5 million and shareholders' equity of $16.7 million. It held $139.5 million in cash and short-term investments against $62.1 million of debt, a net cash position of $77.5 million. Its current ratio was 3.95. In the latest quarter (ended September 30, 2024) total assets were $85.0 million and equity -$11.1 million.
Related: SYRS income statement, SYRS cash flow statement, SYRS key metrics. See the SYRS stock overview for the latest quote and news.
SYRS balance sheet FAQ
What are Syros Pharmaceuticals's total assets?
Syros Pharmaceuticals reported total assets of $168.2 million at the end of fiscal 2023 (December 31, 2023), compared with $244.5 million a year earlier.
How much debt does Syros Pharmaceuticals have?
Syros Pharmaceuticals had $62.1 million of total debt at the end of fiscal 2023, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 3.73.
How much cash does Syros Pharmaceuticals have?
Syros Pharmaceuticals held $139.5 million in cash and short-term investments at the end of fiscal 2023; with $62.1 million of debt that is net cash of $77.5 million.
What is Syros Pharmaceuticals's book value?
Syros Pharmaceuticals's shareholders' equity (book value) was $16.7 million at the end of fiscal 2023, or $0.59 per share.
What is Syros Pharmaceuticals's current ratio?
Syros Pharmaceuticals had current assets of $145.0 million and current liabilities of $36.7 million, a current ratio of 3.95 (it can cover its short-term obligations).